Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects

T. Meloni, G. Forteleoni, M. Serra, S. Daniotti, L. Negri, P. Giuntini, L. Canepa, G. F. Gaetani

Research output: Contribution to journalArticle

Abstract

Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically changes of hematologic tests were observed.

Original languageEnglish
Pages (from-to)418-420
Number of pages3
JournalJournal of Clinical Pharmacology
Volume22
Issue number8-9
Publication statusPublished - 1982

Fingerprint

Feprazone
Glucosephosphate Dehydrogenase
Anti-Inflammatory Agents
Erythrocytes
Glucosephosphate Dehydrogenase Deficiency
Pentose Phosphate Pathway
Hematologic Tests
Pediatrics
Glucose
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Meloni, T., Forteleoni, G., Serra, M., Daniotti, S., Negri, L., Giuntini, P., ... Gaetani, G. F. (1982). Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects. Journal of Clinical Pharmacology, 22(8-9), 418-420.

Feprazone : Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects. / Meloni, T.; Forteleoni, G.; Serra, M.; Daniotti, S.; Negri, L.; Giuntini, P.; Canepa, L.; Gaetani, G. F.

In: Journal of Clinical Pharmacology, Vol. 22, No. 8-9, 1982, p. 418-420.

Research output: Contribution to journalArticle

Meloni, T, Forteleoni, G, Serra, M, Daniotti, S, Negri, L, Giuntini, P, Canepa, L & Gaetani, GF 1982, 'Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects', Journal of Clinical Pharmacology, vol. 22, no. 8-9, pp. 418-420.
Meloni T, Forteleoni G, Serra M, Daniotti S, Negri L, Giuntini P et al. Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects. Journal of Clinical Pharmacology. 1982;22(8-9):418-420.
Meloni, T. ; Forteleoni, G. ; Serra, M. ; Daniotti, S. ; Negri, L. ; Giuntini, P. ; Canepa, L. ; Gaetani, G. F. / Feprazone : Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects. In: Journal of Clinical Pharmacology. 1982 ; Vol. 22, No. 8-9. pp. 418-420.
@article{e1cefc9e6cfb47e19c10a6f84866bc35,
title = "Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects",
abstract = "Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically changes of hematologic tests were observed.",
author = "T. Meloni and G. Forteleoni and M. Serra and S. Daniotti and L. Negri and P. Giuntini and L. Canepa and Gaetani, {G. F.}",
year = "1982",
language = "English",
volume = "22",
pages = "418--420",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8-9",

}

TY - JOUR

T1 - Feprazone

T2 - Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects

AU - Meloni, T.

AU - Forteleoni, G.

AU - Serra, M.

AU - Daniotti, S.

AU - Negri, L.

AU - Giuntini, P.

AU - Canepa, L.

AU - Gaetani, G. F.

PY - 1982

Y1 - 1982

N2 - Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically changes of hematologic tests were observed.

AB - Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically changes of hematologic tests were observed.

UR - http://www.scopus.com/inward/record.url?scp=0019988227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019988227&partnerID=8YFLogxK

M3 - Article

C2 - 7130431

AN - SCOPUS:0019988227

VL - 22

SP - 418

EP - 420

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8-9

ER -